Clinical Trial Details

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

Categories (click each to see list of all clinical trials associated with that category): Pediatric (PEDONC)

Current Status: Open

Phase: III (Cancer Control)

Principal Investigator: Beck, Jill

Contact Information:
Angie Boettner
aboettner@unmc.edu

Eligibility: https://clinicaltrials.gov/study/NCT06647953?term=NCT06647953&rank=1#participation-criteria

Summary
I. To determine the overall response rate (complete response [CR] + partial response [PR]) to 2 cycles of window therapy with vincristine, topotecan and cyclophosphamide in children with Types II and III pleuropulmonary blastoma (PPB) using Response Evaluation Criteria in Solid Tumors (RECIST) criteria. SECONDARY OBJECTIVES: I. To estimate 3-year progression-free survival (PFS) and overall survival (OS) in children with Types II and III PPB. II. To estimate 3-year PFS and OS in children with Type I PPB treated with surgery or surgery and chemotherapy using standardized guidelines.